GlycArt Biotechnology AG - Ownership and Business Overview

Life ScienceCompany

GlycArt Biotechnology AG Ownership

Who owns GlycArt Biotechnology AG?

GlycArt Biotechnology AG is owned by Roche Holding AG. It was acquired on July 19, 2005.

Was GlycArt Biotechnology AG formerly PE-backed?

Yes. GlycArt Biotechnology AG was formerly owned by 2 private investors.

GlycArt Biotechnology AG Business Overview

Where is GlycArt Biotechnology AG headquartered?

GlycArt Biotechnology AG is headquartered in Zurich, Switzerland.

What sector is GlycArt Biotechnology AG in?

GlycArt Biotechnology AG is a life science company.

When was GlycArt Biotechnology AG founded?

GlycArt Biotechnology AG was founded in 2000.

Life Science M&A Summary in 2005

Out of 60 sectors in the Mergr database, life science ranked 15 in number of deals in 2005. The largest life science acquisition in 2005 was Ivax - which was acquired by Teva Pharmaceutical Industries for $7.4B.

Join Mergr to view all 77 acquisitions of life science companies in 2005, including 17 acquisitions by private equity firms, and 60 by strategics.

GlycArt Biotechnology AG

Wagistrasse 18,
Zurich, 8952
Switzerland,
41 44 755 61 61

GlycArt is a Swiss biotechnology company focussed on the development and commercialisation of a new generation of antibody products based on its proprietary GlycoMAb technology. GlycArt has generated its own GlycoMAb-based antibody portfolio by in-licensing and acquiring antibodies at early stages of development and applying GlycoMAb to them.


 Subscribe to unlock this and 201,688
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for GlycArt Biotechnology AG

Life Science Companies , Switzerland Companies